Literature DB >> 7683967

Characteristics of cloned cells of mixed müllerian tumor of the human uterus. Carcinoma cells showing myogenic differentiation in vitro.

M Emoto1, H Iwasaki, M Kikuchi, K Shirakawa.   

Abstract

BACKGROUND: To elucidate the relationship between the epithelial and mesenchymal elements of malignant mixed Müllerian tumors (MMMT), the authors examined the biologic properties of two clones of different cell types (designated as FU-MMT-2-C1 and FU-MMT-2-S1) established from a uterine MMMT cell line (FU-MMT-2), which they previously have reported. METHODS AND
RESULTS: By morphologic and immunocytochemical analyses, FU-MMT-2-C1 exhibited features of adenocarcinoma cells, whereas FU-MMT-2-S1 showed characteristics of sarcoma cells with myogenic differentiation. Some FU-MMT-2-C1 cells at confluence differentiated spontaneously into myogenic mesenchymal cells in vitro. In addition, transitional-type cells between epithelial cells and sarcomatous cells were observed in the areas of mesenchymal differentiation in FU-MMT-2-C1 by light and electron microscopic study. Ultrastructurally, the transitional-type cells represented biphasic morphologic characteristics consisting of epithelial and myogenic features, which proved to coexpress epithelial, mesenchymal, and muscle markers by double immunoenzymatic staining. However, no epithelial differentiations were apparent in the sarcoma clone FU-MMT-2-S1. FU-MMT-2-C1 produced tumor in nude mice, the histologic study of which showed a mixture of adenocarcinoma and myogenic sarcomatous elements that resembled the original tumor. Cytogenetic studies demonstrated that these two clones were monoclonal in origin because of the presence of common karyotypic abnormalities in both cells. In addition, the amplified (approximately fourfold to eightfold) c-myc oncogene was found in the cloned cells and the original tumor cells.
CONCLUSIONS: The current results strongly support the theory of single cell origin in uterine MMMT and suggest that the mesenchymal elements originated from primitive Müllerian epithelial cells capable of differentiating into epithelial, mesenchymal, or both elements.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683967     DOI: 10.1002/1097-0142(19930515)71:10<3065::aid-cncr2820711029>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Expression and localization of E-cadherin and β-catenin in uterine carcinosarcoma.

Authors:  Izumi Nishimura; Yoshihiro Ohishi; Yoshinao Oda; Junji Kishimoto; Masafumi Yasunaga; Emi Okuma; Hiroaki Kobayashi; Norio Wake; Masazumi Tsuneyoshi
Journal:  Virchows Arch       Date:  2010-11-03       Impact factor: 4.064

2.  A mixed mesodermal tumor of the cecum: report of a case.

Authors:  A Shimizu; K Ohno; Y Masuda; F Endou; Y Masuda; A Ogata; M Nagai; G Obata; K Asano
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

Review 3.  Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?

Authors:  W G McCluggage
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

Review 4.  Epithelial to mesenchymal transition in the pathogenesis of uterine malignant mixed Müllerian tumours: the role of ubiquitin proteasome system and therapeutic opportunities.

Authors:  I A Voutsadakis
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

5.  Mutations of the Ki-ras oncogene in carcinoma of the endometrium.

Authors:  R F Caduff; C M Johnston; T S Frank
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

6.  Expression and functional regulation of myoglobin in epithelial cancers.

Authors:  Simona Emilia Flonta; Sabrina Arena; Alberto Pisacane; Paolo Michieli; Alberto Bardelli
Journal:  Am J Pathol       Date:  2009-06-18       Impact factor: 4.307

7.  MLH1 promoter hypermethylation in uterine carcinosarcoma rarely coexists with TP53 mutation.

Authors:  Michal Kunc; Anna Gabrych; Bartlomiej Rekawiecki; Adam Gorczynski; Sabine Franke; Johannes Haybaeck; Wojciech Biernat; Piotr Czapiewski
Journal:  Contemp Oncol (Pozn)       Date:  2019-11-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.